

University of Colorado School of Medicine
Curriculum Vitae

Date: 07/17/2017

Frank Irving Scott, MD, MSCE

Address: Division of Gastroenterology
University of Colorado School of Medicine
1635 Aurora Court Room 2.031
Mail Stop 735
Aurora, CO 80045 United States

Education:

2000	BA	University of Pennsylvania (Biology)
2006	MD	Temple University School of Medicine
2012	MSCE	University of Pennsylvania (Masters of Science in Clinical Epidemiology)

Postgraduate Training and Fellowship Appointments:

2006-2009	Intern and resident in Internal Medicine, New York-Presbyterian Hospital/Weill Cornell Medical College
2009-2012	Fellowship in Gastroenterology, University of Pennsylvania
2012-2013	Fellowship in Inflammatory Bowel Disease, University of Pennsylvania

Faculty Appointments:

2015	Assistant Professor of Epidemiology in Biostatistics and Epidemiology, University of Pennsylvania School of Medicine (Secondary)
2015	Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine
2016-Present	Assistant Professor of Medicine at the University of Colorado School of Medicine

Other Appointments:

2013-2015	Investigator in Training, Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
2015	Senior Scholar, Clinical Epidemiology Unit, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine
2016-Present	Adjunct Scholar, Clinical Epidemiology Unit, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine

Specialty Certification:

2009	Board Certification in Internal Medicine - American Board of Internal Medicine
------	--

2012	Board Certification in Gastroenterology - American Board of Internal Medicine
------	---

Licensure:

2008-2009	New York State Office of Professions
2009-2012	Pennsylvania Department of State (Graduate Medical Trainee)
2010-2015	Pennsylvania Department of State
2016	Colorado Department of Regulatory Agencies

Awards, Honors and Membership in Honorary Societies:

2004	Outstanding Academic Achievement in Medical Biochemistry, Temple University
2006	Emmanuel M. Weinberger Award in Infectious Diseases, Temple University
2006	Alpha Omega Alpha, Temple University
2008	Assistant Chief Resident, Department of Medicine, New York - Presbyterian/Weill Cornell Medical College
2012	Edward Raffensperger Award for Excellence in GI Fellow Teaching, Division of Gastroenterology, Department of Medicine, University of Pennsylvania

Memberships in Professional and Scientific Societies and Other Professional Activities:National:

2009-Present	American College of Gastroenterology (Member)
2009-Present	American Gastroenterology Association (Member)
2010-Present	Crohn's and Colitis Foundation (Member)
2015-Present	Crohn's and Colitis Foundation Research Initiatives National Scientific Advisory Committee
2016-Present	Crohn's and Colitis Foundation Rising Educators Academics and Clinicians Helping IBD (REACH-IBD) Steering Committee member

Editorial Positions:

2013-Present	Reviewer, Pharmacoepidemiology and Drug Safety
2013-Present	Reviewer, Inflammatory Bowel Disease
2013-Present	Reviewer, Journal of Medical Economics
2014-Present	Reviewer, Gastroenterology
2015-Present	Reviewer, Clinical Gastroenterology and Hepatology
2016-Present	Reviewer, BMC Surgery
2016-Present	Reviewer, Childhood Obesity
2016-Present	Reviewer, Alimentary Pharmacology and Therapeutics
2016-Present	Reviewer, JAMA Pediatrics
2016-Present	Reviewer, Science

Academic and Institutional Committees:

2013-2015	Clinical Competency Committee, Division of Gastroenterology, University of Pennsylvania
-----------	---

Major Academic and Clinical Teaching Responsibilities:

2011-2015	Small Group Preceptor: Gastrointestinal Pathophysiology, University of Perelman Pennsylvania School of Medicine
2011-2012	Teaching Assistant, Evidence Based Medicine, University of Pennsylvania School of Medicine
2012-2015	Lecturer in first-year medical school curriculum: Inflammatory Bowel Disease Pathophysiology and Pharmacotherapy, University of Pennsylvania
2013-2015	Lecturer in Frontiers in Gastroenterology medical school curriculum course, lecture title "The Role of Innate and Adaptive Immune Responses in IBD." University of Pennsylvania
2013-2015	"Cases in Inflammatory Bowel Disease", GI Fellows, University of Pennsylvania
2014-2015	"Inpatient Management of Inflammatory Bowel Disease", GI fellow lecture, University of Pennsylvania
2016-Present	Small Group Preceptor: Gastrointestinal Pathophysiology, University of Colorado School of Medicine

Lectures by Invitation:

Apr, 2014	"What's New in Research for IBD Treatment", Crohn's and Colitis Foundation of America Annual Patient Education Day, Thomas Jefferson University Hospital, Philadelphia, PA
May, 2014	"The Risk of a Second Non-Melanoma Skin Cancer with Thiopurine and Anti-TNF Use in Inflammatory Bowel Disease" American College of Gastroenterology Annual Scientific Meeting, Philadelphia, PA
May, 2014	"The impact of age-specific risks of lymphoma on the decision to use combination therapy with infliximab and azathioprine versus infliximab alone: A Markov Model" - Digestive Diseases Week, Chicago, IL
Sep, 2014	"Modeling treatment decisions in IBD: From diagnosis to combination therapy and beyond." Gastroenterology Research Conference, Oregon Health & Science University (OHSU), Portland, OR
Nov, 2014	"Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis", American College of Rheumatology Annual Meeting, San Francisco, CA
Nov, 2014	"Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study", American College of Rheumatology Annual Meeting, San Francisco, CA
Nov, 2014	"Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients", American College of Rheumatology Annual Meeting, San Francisco, CA
Jan, 2015	"Modeling treatment decisions in inflammatory bowel disease", Center for Clinical Epidemiology and Biostatistics Clinical Epidemiology Seminar, University of Pennsylvania, Philadelphia, PA
May, 2015	"Effect of Immunosuppressive Therapies on Mucinous Pancreatic Cyst Progression", Digestive Diseases Week, Washington, DC

May, 2015	"Validation of small bowel obstruction and abdominal surgery diagnostic codes in an electronic medical records database", Digestive Diseases Week, Washington, DC
May, 2016	"Electronic medical record validation of coding algorithm for intra-abdominal surgeries and adhesion-related complications." IMS Health Scientific Forum, Washington, DC.
June, 2016	"When to Start and Switch Biologics in IBD", Rocky Mountain Updates in Gastroenterology, Denver, CO
Oct, 2016	"The Microbiome and IBD: What we do and don't know yet". Keynote Address, CCFA Patient Education Day, Denver, CO
Feb, 2017	"Association between cancer recurrence with immunosuppression in immune-mediated diseases." Massachusetts General Hospital GI Grand Rounds, Boston, MA
May, 2017	"Minding the Gaps: Combining Patient-Centric Valuation, Observational Data Analysis, and Decision Modeling to Deliver Patient-Centered Comparative Effectiveness Research." Workshop Presenter, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Boston, MA
June, 2017	"Quantitative Approaches to Defining Optimal Treatment Strategies in IBD." American Gastroenterological Association and Chinese Society for Gastroenterology Symposium, Beijing, China
June, 2017	"Update in Biologics in IBD", Rocky Mountain Updates in Gastroenterology, Denver CO
June, 2017	"Primary care in IBD", Rocky Mountain Updates in Gastroenterology, Denver CO

Bibliography:

Research Publications, peer reviewed (print or other media):

1. **Scott FI**, McConnell RA, Lewis ME, Lewis JD: Increasing complexity of clinical research in gastroenterology: implications for the training of clinician-scientists. Am Journal Gastroenterology 107(4): 496-500, Apr 2012.
2. **Scott FI**, Osterman MT, Mahmoud NN, Lewis JD: Secular trends in small-bowel obstruction and adhesiolysis in the United States: 1988-2007. Am Journal Surgery 204(3): 315-20, Sep 2012. PMID: PMC3419344
3. **Scott FI**, Osterman MT, McConnell RA, Lorusso M, Aberra F, Kerner C, Lichtenstein GR, Lewis JD: Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflammatory Bowel Diseases 19(12): 2625-33, Nov 2013.
4. Mamtani R, Haynes K, Finkelman BS, **Scott FI**, Lewis JD: Distinguishing incident and prevalent diabetes in an electronic medical records database. Pharmacoepidemiology and Drug Safety 23(2): 111-8, Feb 2014. PMID: PMC3929581

5. Agarwalla A, Small AJ, Mendelson AH, **Scott FI**, Kochman ML.: Risk of recurrent or refractory strictures and outcome of endoscopic dilation for radiation-induced esophageal strictures. Surgical Endoscopy 2014 Notes: Epub ahead of print, 2014 October.
6. Mamtani R, Boursi B, **Scott FI**, Goldberg DF, Keefe SM, Vaughn DJ, Malkowicz SB, Lewis JD: Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database. Cancer Epidemiology, Biomarkers & Prevention 24(1): 303-307, January 2015 Notes: Epub ahead of print, 2014 November.
7. Mendelson AH, Small AJ, Agarwalla A, **Scott FI**, Kochman ML: Esophageal anastomotic strictures: outcomes of endoscopic dilation, risk of recurrence and refractory stenosis and effect of foreign body removal. Clinical Gastroenterology and Hepatology 13(2): 263-271, Feb 2015 Notes: Epub ahead of print, 2014 July.
8. **Scott FI**, Vajravelu RK, Bewtra M, Mamtani R, Lee D, Goldberg DS, Lewis, JD: The Benefit to Risk Balance of Combining Infliximab with Azathioprine Varies With Age: A Markov Model. Clinical Gastroenterology and Hepatology 13(2): 302-309, February 2015 Notes: Epub ahead of print, 2014 August.
9. Horton DB, **Scott FI**, Haynes K, Putt ME, Rose CD, Lewis JD, Strom BL: Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case-Control Study. Pediatrics 136(2): e333-343, August 2015.
10. Heno MP, Bewtra M, Osterman MT, Aberra FN, **Scott FI**, Lichtenstein GR, Kraschnewski J, Lewis JD: Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection. Inflammatory Bowel Diseases 21(10): 2262-2271, October 2015.
11. **Scott FI***, Mamtani R*, Brensinger CM, Haynes K, Cheisa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, and Lewis JD: Risk of non-melanoma skin cancer in patients with a history of NMSC with the use of immunosuppressant and biologic agents in autoimmune disease JAMA Dermatology Feb 2016;152(2):164-72.
12. Goldberg DS, French B, Lewis JD, **Scott FI**, Mamtani R, Gilroy R, Halpern SD, Abt PL.: Liver transplant center variability in accepting organ offers and its impact on patient survival. J Hepatol Nov 2015 Notes: Epub Ahead of Print.
13. Horton DB, **Scott FI**, Haynes K, Putt ME, Rose CD, Lewis JD, Strom BL.: Antibiotic Exposure, Infection, and the Development of Pediatric Psoriasis: A Nested Case-Control Study. JAMA Dermatol Feb 2016;152(2):191-9.
14. Goldberg DS, French B, Lewis JD, **Scott FI**, Mamtani R, Gilroy R, Halpern SD, Abt PL. Liver transplant center variability in accepting organ offers and its impact on patient survival. J Hepatol. Apr 2016;64(4):843-51.
15. Zhang F, Mamtani R, **Scott FI**, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf. Jun 2016;25(6):628-36.

16. Mamtani R, Yang YX, **Scott FI**, Lewis JD, Boursi B. Association between itraconazole, a hedgehog-inhibitor, and bladder cancer. J Urol. Aug 2016;196(2):343-8.
17. **Scott FI**, Mamtani R, Hanes K, Goldberg DS, Mahmoud NN, Lewis JD. Validation of a coding algorithm for intra-abdominal surgeries and adhesion-related complications in an electronic medical records database. Pharmacoepidemiol Drug Saf. Apr 2016;25(4):405-12.
18. Mamtani R, Lewis JD, **Scott FI**, Ahmad T, Goldberg DS, Yang YX, Boursi B. Disentangling the association between statins, cholesterol, and colorectal cancer: A nested case-control study. PLOS Medicine. 2016 March. Note: Epub Ahead of print.
19. **Scott FI**, Horton DB, Mamtani R, Haynes K, Goldberg DS, Lee DY, Lewis JD. Administration of Antibiotics to Children Before Age 2 Years Increases Risk for Childhood Obesity. Gastroenterology. Jul 2016;151(1):120-129.
20. Shelton E, Laharie D, **Scott FI**, Mamtani R, Lewis JD, Colombel JF, Ananthakrishnan AN. Cancer recurrence with immunosuppressive therapy in immune mediated diseases: A systematic review and meta-analysis. Gastroenterology Jul 2016;151(1):97-109.
21. Mamtani R, Lewis JD, **Scott FI**, Ahmad T, Goldberg DS, Yang YX, Boursi B. Disentangling the association between statins, cholesterol, and colorectal cancer: A nested case-control study. PLOS Medicine. 2016 March. Note: Epub Ahead of print.
22. Mamtani R, Clark AS, **Scott FI**, Brensinger CM, Boursi B, Chen L, Xie F, Yun H, Osterman MT, Curtis JR, Lewis JD. Association between breast cancer recurrence with immunosuppression in rheumatoid arthritis and inflammatory bowel disease: A cohort study. Arthritis Rheumatol. 2016 Oct;68(10):2403-11.
23. Agarwal A, **Scott FI**, Ahmad NA, Chandrasekhara V. Chronic immunosuppression does not potentiate the malignant progression of mucinous pancreatic cystic lesions. Pancreatol. 2016 Sep-Oct;16(5):900-4
24. Vajravelu R, Osterman MT, Aberra FN, Roy JA, Lichtenstein GR, Mamtani R, Goldberg DS, Lewis JD, **Scott FI**. Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization. Inflamm Bowel Diseases. July 2017 In Press.

Research Publications, peer-reviewed reviews:

1. **Scott FI**: Advanced Training in IBD: Increased Exposure to Increasingly Complex Diseases. AGA Perspectives. Gary W. Falk, MD (eds.). AGA Institute, Bethesda, MD, 10(6): 22-23, December 2014.
2. **Scott FI** and Lichtenstein GR: Inflicting Confusion. AHRQ WebM&M [serial online]. Available at: <http://webmm.ahrq.gov/case.aspx?caseID=351>. (eds.). June 2015.

3. **Scott FI** and Osterman MT: Natalizumab for Crohn's Disease: Down but Not Out. Clin Gastroenterol Hepatol. 2015 Nov;13(11):1926-8.
4. **Scott FI** and Lichtenstein GR: Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in review. Current Treatment Options in Gastroenterology. Mar 2016;14(1):91-102
5. **Scott FI** and Lichtenstein GR: Approach to the Patient with Mild Crohn's Disease: a 2016 Update. Sep 2016;18(9):50.

Abstracts:

1. Bosworth BP, **Scott FI**, Jacob VE, Scherl, EJ. Long-term follow-up of the use of rifaximin in maintaining clinical remission in moderate and severe Crohn's disease. Am Journal Gastroenterology 103: S423, 2008.
2. McConnell RA, Carr RM, Hwang A, **Scott FI**, Wu GD : Headache With Hematochezia: A Case of Sumatriptan-Induced Ischemic Colitis. Gastroenterology. Accepted Abstract, Poster session, Digestive Diseases Week, May 2013, 144: S903, May 2013.
3. **Scott FI**, McConnell, R, Lorusso, M, Lewis, JD: The Impact of JC Virus Antibody Testing on Treatment Selection in Patients with Crohn's Disease who are Primary Non-responders to Infliximab: A Decision Analysis. Gastroenterology. Accepted Abstract, Poster Session, Digestive Diseases Week May 2013 (eds.). 144: S648, May 2013.
4. Mendelson AH, Small AJ, Agarwalla A, **Scott FI**, Kochman ML: Clinical and Procedural Predictors of Refractory Anastomotic and Radiation-Induced Strictures. Gastrointestinal Endoscopy Page: AB518, May 2014 Notes: Accepted Abstract, Poster session, Digestive Diseases Week May 2014.
5. Horton DB, **Scott FI**, Haynes K, Putt ME, Rose CD, Lewis JD, Strom BL: Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study. Arthritis and Rheumatology 66(11): s412-413, October 2014 Notes: Accepted abstract and Poster Session, American College of Rheumatology 2014.
6. Patel U, Lichtenstein GR, **Scott FI**: Malignancy Outcomes in Inflammatory Bowel Disease Patients on Immune Modulators and Anti-Tumor Necrosis Factor Therapy. Am Journal Gastroenterology 109(s2): s484, October 2014 Notes: Accepted Abstract, Poster session, American College of Gastroenterology 2014.
7. Yun H, Winthrop KL, Chen L, Smith W, Chan B, Fenglong X, Taylor A, Mamtani R, **Scott FI**, Lewis JD, and Curtis JR: Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients. Arthritis and Rheumatology 66(11): S681-682, October 2014 Notes: Accepted abstract, Poster session, American College of Rheumatology.

8. Henao MP, Bewtra M, Osterman MT, Aberra F, Scott FI, Lichtenstein FI, Kraschnewski J, Lewis JD: Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection. Accepted Abstract, Poster Session, Digestive Diseases Week 2015 May 2015.
9. Mudireddy P, **Scott FI**, Lichtenstein GR: Predictors of early and late unplanned re-admissions in IBD patients Accepted abstract, Poster session, Digestive Diseases Week 2015 May 2015.
10. Mudireddy P, **Scott FI**, Lichtenstein GR: Unplanned Hospital Readmission: Rates and Causes in Patients with Inflammatory Bowel Disease: A Critical Analysis Accepted abstract, Poster session, Digestive Diseases Week 2015 May 2015.
11. Vajravelu RK, Lewis JD, Aberra FA, Osterman MT, Lichtenstein GR, **Scott FI**: Predictors of Indeterminate Quantiferon-TB Gold Testing in Inflammatory Bowel Disease and Impact on Clinical Outcomes. Accepted Abstract, Poster Session, Digestive Diseases Week 2015 May 2015.
12. **Scott FI**, Shah Y, Lasch K, Luo M, Lewis JD. Determining the Optimal Position for Vedolizumab in the Current Treatment Paradigm for Ulcerative Colitis: A Markov Model. Accepted Abstract, Oral Presentation, Digestive Diseases Week 2016, May 2016.
13. Shah Y, Vajravelu RK, Bewtra M, Mamtani R, Lewis JD, **Scott FI**. The Impact of Gender on Age-Specific Risks and Benefits of Combination Therapy With Infliximab and Azathioprine Versus Infliximab Alone: A Markov Model. Accepted Abstract, Poster Presentation, Digestive Diseases Week 2016, May 2016.
14. Mendoza Ladd AH, **Scott FI**, Grace R, Bownik H, Lichtenstein GR. Dose Escalation of Vedolizumab From Every 8 Weeks to Every 4 or 6 Weeks Enables Patients With Inflammatory Bowel Disease to Recapture Response. Accepted Abstract, Poster Presentation, Digestive Diseases Week 2016, May 2016.

Editorials, Reviews, Chapters, including participation in committee reports (print or other media):

1. **Scott FI**, Aberra F. VSL#3 for Ulcerative Colitis: Growing Evidence? Gastroenterology 140(5): 1685-6; discussion 1686-7, May 2011.
2. **Scott FI**, Lynch JP. Mechanisms of Gastrointestinal Carcinogenesis Molecular Pathology of Neoplastic Gastrointestinal Diseases. Sepulveda, Antonia R., Lynch, John P. (eds.). Springer, Jan 2013 Notes: ISBN: 978-1-4614-6014-5.
3. **Scott FI**, Osterman MT. Medical Management of Crohn Disease. Clinics in Colon and Rectal Surgery 26(2): 67-74, Jun 2013. PMID: PMC3709949
4. **Scott FI**, Lichtenstein Gary R: Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology 12(1): 59-75, Mar 2014.

5. **Scott FI** and Aberra, F: Prebiotics, Probiotics and Antibiotics for Ulcerative Colitis. Medical Therapy of Ulcerative Colitis. Gary R. Lichtenstein, MD (eds.). Springer, January 2015 Notes: Chapter, ISBN-13: 978-1493916764
6. **Scott FI** and Lichtenstein, GR: The evaluation, diagnosis, and treatment of Inflammatory bowel diseases over the past 100 years: A brief review. Endoscopy in Inflammatory Bowel Disease. Kozarek RA, Chiorean M, Wallace M (eds.). Springer, 2015.
7. **Scott FI** and Lichtenstein GR: Chapter 13: Inflammatory Bowel Disease. Digestive Diseases Self-Education Program (DDSEP) 8: Sweetser S, Christie JA, Oxentenko AS (eds). American Gastroenterological Association, 2016.
8. **Scott FI** and Mamtani R. Antibiotics and Obesity-A Burgeoning or Thinning Argument? JAMA Pediatr. 2017 Feb 1;171(2):118-120.